<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">02809</article-id><article-id pub-id-type="doi">10.7554/eLife.02809</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology and Stem Cells</subject></subj-group></article-categories><title-group><article-title>Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-12184"><name><surname>Blum</surname><given-names>Barak</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12384"><name><surname>Roose</surname><given-names>Adam N</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12385"><name><surname>Barrandon</surname><given-names>Ornella</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12386"><name><surname>Maehr</surname><given-names>René</given-names></name><aff><addr-line><named-content content-type="department">Program in Molecular Medicine</named-content></addr-line>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12387"><name><surname>Arvanites</surname><given-names>Anthony C</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12388"><name><surname>Davidow</surname><given-names>Lance S</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12389"><name><surname>Davis</surname><given-names>Jeffrey C</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12390"><name><surname>Peterson</surname><given-names>Quinn P</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-7036"><name><surname>Rubin</surname><given-names>Lee L</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-9075"><name><surname>Melton</surname><given-names>Douglas A</given-names></name><aff><addr-line><named-content content-type="department">Department of Stem Cell and Regenerative Biology</named-content></addr-line>, <institution>Harvard Stem Cell Institute, Harvard University</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country><email>dmelton@harvard.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1154"><name><surname>Okano</surname><given-names>Hideyuki</given-names></name><role>Reviewing editor</role><aff><institution>Keio University School of Medicine</institution>, <country>Japan</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>09</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02809</elocation-id><supplementary-material><ext-link xlink:href="elife-02809-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>16</day><month>03</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Blum et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Blum et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Dysfunction or death of pancreatic β cells underlies both types of diabetes. This functional decline begins with β cell stress and de-differentiation. Current drugs for T2D lower blood glucose levels, but they do not directly alleviate β cell stress nor prevent, let alone reverse, β cell de-differentiation. We show here that Urocortin 3 (Ucn3), a marker for mature β cells, is down-regulated in the early stages of T2D in mice and when β cells are stressed <italic>in vitro</italic>. Using an insulin expression-coupled lineage tracer, with Ucn3 as a reporter for the mature β cell state, we screen for factors that reverse β cell de-differentiation. We find that a small molecule inhibitor of TGFβ receptor I (Alk5) protects cells from the loss of key β cell transcription factors and restores a mature β cell identity even after exposure to prolonged and severe diabetes.</p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>Alk5 inhibitor II</kwd><kwd>Beta cells</kwd><kwd>dedifferentiation</kwd><kwd>diabetes</kwd><kwd>Ucn3</kwd><kwd>Tgf-beta</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were performed in compliance with the Harvard University International Animal Care and Use Committee (IACUC) guidelines (protocol #93-15).</p></fn><fn fn-type="other"><p>Human subjects: Institutional review board approval for research use of human tissue was obtained from the Harvard University Faculty of Arts and Sciences. Human islets were obtained from NDRI (The National Disease Research Interchange). Donor anonymity was preserved, and the human tissue was collected under applicable regulations and guidelines regarding consent, protection of human subjects and donor confidentiality</p></fn></fn-group></back></article>